The value of epigenetic markers in esophageal cancer

Frontiers of Medicine in China

Volumn 4, Issue 4, 2010, Pages 378-384

  Zhang, Xiao Mei ^a   Guo, Ming Zhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

DNA methylation; dysplasia; epigenetics; esophageal cancer

Indexed keywords

ADENOCARCINOMA; DNA METHYLATION; EARLY DIAGNOSIS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; HUMAN; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; PROGNOSIS;

EID: 78650699070     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-010-0230-3     Document Type: Review

References (66)

1. Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Hu N, Dawsey S M, Wu M, Bonney G E, He L J, Han X Y, Fu M, Taylor P R. Family history of oesophageal cancer in Shanxi Province. Int J Epidemiol, 1992, 21(5): 877-822.
3. Yang C S. Research on esophageal cancer in China: a review. Cancer Res, 1980, 40(8 Pt 1): 2633-2644.
4. Taylor P R, Dawsey S M, Hu N, Albanes D, Wu M. Nutritional intervention to prevent hereditary cancer. J Natl Cancer Inst Monogr, 1995, (17): 43-47.
5. Carter C L, Hu N, Wu M, Lin P Z, Murigande C, Bonney G E. Segregation analysis of esophageal cancer in 221 high-risk Chinese families. J Natl Cancer Inst, 1992, 84(10): 771-776.
6. Muñoz N. Epidemiological aspects of oesophageal cancer. Endoscopy, 1993, 25(9): 609-612.
7. Nielsen N H, Mikkelsen F, Hansen J P. Oesophageal cancer in Greenland: selected epidemiological and clinical aspects. J Cancer Res Clin Oncol, 1979, 94(1): 69-80.
8. Cameron A J. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am, 1997, 26(3): 487-494.
9. Okano J, Snyder L, Rustgi A K. Genetic alterations in esophageal cancer. Methods Mol Biol, 2003, 222: 131-145.
10. Vogelstein B, Kinzler K W. The multistep nature of cancer. Trends Genet, 1993, 9(4): 138-141.
11. Zhang W, Glöckner S C, Guo M, Machida E O, Wang D H, Easwaran H, van Neste L, Herman J G, Schuebel K E, Watkins D N, Ahuja N, Baylin S B. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res, 2008, 68(8): 2764-2772.
12. Wang J S, Guo M, Montgomery E A, Thompson R E, Cosby H, Hicks L, Wang S, Herman J G, Canto M I. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol, 2009, 104(9): 2153-2160.
13. Carmona F J, Esteller M. Epigenomics of human colon cancer. Mutat Res, 2010, 693(1-2): 53-60.
14. Mokrowiecka A, Wierzchniewska-Ławska A, Smolarz B, Romanowicz-Makowska H, Malecka-Panas E. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasiadysplasia-adenocarcinoma sequence]. Pol Merkur Lekarski, 2009, 26(155): 385-389.
15. Kohler E M, Brauburger K, Behrens J, Schneikert J. Contribution of the 15 amino acid repeats of truncated APC to beta-catenin degradation and selection of APC mutations in colorectal tumours from FAP patients. Oncogene, 2010, 29(11): 1663-1671.
16. Holliday R. The inheritance of epigenetic defects. Science, 1987, 238(4824): 163-170.
17. Jones P A, Baylin S B. The fundamental role of epigenetic events in cancer. Nat Rev Genet, 2002, 3(6): 415-428.
18. Riggs A D, Pfeifer G P. X-chromosome inactivation and cell memory. Trends Genet, 1992, 8(5): 169-174.
19. Ali A B, Iau P T, Sng J H. Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours. Med Oncol, 2010 Feb 5.
20. Merlo A, Herman J G, Mao L, Lee D J, Gabrielson E, Burger P C, Baylin S B, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med, 1995, 1(7): 686-692.
21. Guo M, House M G, Suzuki H, Ye Y, Brock M V, Lu F, Liu Z, Rustgi A K, Herman J G. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer, 2007, 121(6): 1219-1226.
22. Guo M, House M G, Akiyama Y, Qi Y, Capagna D, Harmon J, Baylin S B, Brock M V, Herman J G. Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer, 2006, 119(9): 2078-2083.
23. Aguilera O, Fraga M F, Ballestar E, Paz M F, Herranz M, Espada J, García JM, Muñoz A, Esteller M, González-Sancho JM. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene, 2006, 25(29): 4116-4121.
24. Martinez R, Setien F, Voelter C, Casado S, Quesada M P, Schackert G, Esteller M. CpG island promoter hypermethylation of the proapoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis, 2007, 28(6): 1264-1268.
25. Blanco D, Vicent S, Fraga M F, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga L M. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia, 2007, 9(10): 840-852.
26. Yue W, Sun Q, Dacic S, Landreneau R J, Siegfried JM, Yu J, Zhang L. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis, 2008, 29(1): 84-92.
27. Lee B B, Lee E J, Jung E H, Chun H K, Chang D K, Song S Y, Park J, Kim D H. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res, 2009, 15(19): 6185-6191.
28. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grützmann R, Pilarsky C, Sledziewski A. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem, 2008, 54(2): 414-423.
29. Atherfold P A, Jankowski J A. Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol, 2006, 20(5): 813-827.
30. Dulai G S, Guha S, Kahn K L, Gornbein J, Weinstein W M. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology, 2002, 122(1): 26-33.
31. Corley D A, Levin T R, Habel L A, Weiss N S, Buffler P A. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology, 2002, 122(3): 633-640.
32. McManus D T, Olaru A, Meltzer S J. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res, 2004, 64(5): 1561-1569.
33. Bian Y S, Osterheld M C, Fontolliet C, Bosman F T, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology, 2002, 122(4): 1113-1121.
34. Wong D J, Paulson T G, Prevo L J, Galipeau P C, Longton G, Blount P L, Reid B J. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res, 2001, 61(22): 8284-8289.
35. Klump B, Hsieh C J, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology, 1998, 115(6): 1381-1386.
36. Wong D J, Barrett M T, Stöger R, Emond M J, Reid B J. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res, 1997, 57(13): 2619-2622.
37. Eads C A, Lord R V, Wickramasinghe K, Long T I, Kurumboor S K, Bernstein L, Peters J H, DeMeester S R, DeMeester T R, Skinner K A, Laird P W. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res, 2001, 61(8): 3410-3418.
38. Guo M, Ren J, House M G, Qi Y, Brock M V, Herman J G. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res, 2006, 12(15): 4515-4522.
39. Guo M, Ren J, Brock M V, Herman J G, Carraway H E. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics, 2008, 3(6): 336-341.
40. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton J P, David S, Agarwal R, Selaru F M, Sato F, Abraham J M, Beer D G, Mori Y, Shimada Y, Meltzer S J. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer, 2008, 123(10): 2331-2336.
41. Jin Z, Hamilton J P, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer D G, Agarwal R, Abraham J M, Meltzer S J. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev, 2008, 17(1): 111-117.
42. Jin Z, Mori Y, Hamilton J P, Olaru A, Sato F, Yang J, Ito T, Kan T, Agarwal R, Meltzer S J. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer, 2008, 112(1): 43-49.
43. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton J P, Ito T, Wang S, David S, Agarwal R, Beer D G, Abraham JM, Meltzer S J. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res, 2007, 13(21): 6293-6300.
44. Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene, 2007, 26(43): 6332-6340.
45. Kuester D, Dar A A, Moskaluk C C, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia, 2007, 9(3): 236-245.
46. Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression. Clin Cancer Res, 2006, 12(22): 6637-6642.
47. Anupam K, Tusharkant C, Gupta S D, Ranju R. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol, 2006, 12(37): 6041-6045.
48. Clément G, Braunschweig R, Pasquier N, Bosman F T, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol, 2006, 208(1): 100-107.
49. Zou H, Osborn N K, Harrington J J, Klatt K K, Molina J R, Burgart L J, Ahlquist D A. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 2005, 14(4): 830-834.
50. Campbell N P, Villaflor V M. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol, 2010, 16(30): 3793-3803.
51. Hyngstrom J R, Posner M C. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol, 2010, 101(4): 299-304.
52. Kim M P, Correa A M, Lee J, Rice D C, Roth J A, Mehran R J, Walsh G L, Ajani J A, Maru D M, Chang J Y, Marom E M, Macapinlac H A, Lee J H, Vaporciyan A A, Rice T, Swisher S G, Hofstetter W L. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg, 2010, 90(3): 884-890, discussion 890-891.
53. Metzger R, Heukamp L, Drebber U, Bollschweiler E, Zander T, Hoelscher A H, Warnecke-Eberz U. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics, 2010, 11(8): 1105-1113.
54. Esteller M, Garcia-Foncillas J, Andion E, Goodman S N, Hidalgo O F, Vanaclocha V, Baylin S B, Herman J G. Inactivation of the DNArepair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med, 2000, 343(19): 1350-1354.
55. Rivera A L, Pelloski C E, Gilbert M R, Colman H, De La Cruz C, Sulman E P, Bekele B N, Aldape K D. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol, 2010, 12(2): 116-121.
56. Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression. Clin Cancer Res, 2006, 12(22): 6637-6642.
57. Hamilton J P, Sato F, Greenwald B D, Suntharalingam M, Krasna M J, Edelman M J, Doyle A, Berki A T, Abraham J M, Mori Y, Kan T, Mantzur C, Paun B, Wang S, Ito T, Jin Z, Meltzer S J. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol, 2006, 4(6): 701-708.
58. Mandelker D L, Yamashita K, Tokumaru Y, Mimori K, Howard D L, Tanaka Y, Carvalho A L, Jiang WW, Park H L, Kim M S, Osada M, Mori M, Sidransky D. PGP9. 5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res, 2005, 65(11): 4963-4968.
59. Li L W, Yu X Y, Yang Y, Zhang C P, Guo L P, Lu S H. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer, 2009, 125(7): 1505-1513.
60. Brock M V, Gou M, Akiyama Y, Muller A, Wu T T, Montgomery E, Deasel M, Germonpr'e P, Rubinson L, Heitmiller R F, Yang S C, Forastiere A A, Baylin S B, Herman J G. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res, 2003, 9(8): 2912-2919.
61. Kawakami K, Brabender J, Lord R V, Groshen S, Greenwald B D, Krasna MJ, Yin J, Fleisher A S, Abraham JM, Beer D G, Sidransky D, Huss H T, Demeester T R, Eads C, Laird PW, Ilson D H, Kelsen D P, Harpole D, Moore M B, Danenberg K D, Danenberg P V, Meltzer S J. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst, 2000, 92(22): 1805-1811.
62. Lee E J, Lee B B, Kim J W, Shim Y M, Hoseok I, Han J, Cho E Y, Park J, Kim D H. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer, 2006, 42(7): 972-980.
63. Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene, 2007, 26(43): 6332-6340.
64. Ohta M, Mimori K, Fukuyoshi Y, Kita Y, Motoyama K, Yamashita K, Ishii H, Inoue H, Mori M, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer, 2008, 98(2): 410-417.
65. Lee E J, Lee B B, Han J, Cho E Y, Shim YM, Park J, Kim D H. CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int J Cancer, 2008, 123(9): 2073-2079.
66. Zare M, Jazii F R, Alivand M R, Nasseri N K, Malekzadeh R, Yazdanbod M. Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer, 2009, 9: 24.